A phase 2, single agent study of CI-1033 administered at two doses in ovarian cancer patients who failed platinum therapy

Campos, S. M.; Seiden, Michael V.; Oza, A.; Plante, M.; Potkul, Ronald K.; Hamid, Oday; Lenehan, Peter F.; Kaldjian, Eric P.; Jordan, Cheryl; Hirte, Hal W.

doi:10.1200/jco.2004.22.14_suppl.5054

Cited by 13 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Campos et al (57) reported a phase II study of CI-1033 administered as a single agent in 105 ovarian cancer patients who had failed platinum therapy. Patients were randomized to either a 50-or a 200-mg dose of CI-1033 taken orally for 21 days of a 28-day cycle.…”

Section: Canertinib/ci-1033mentioning

confidence: 99%

The emerging role of epidermal growth factor receptor inhibitors in ovarian cancer

Palayekar

Herzog

2008

Int J Gynecol Cancer

View full text Add to dashboard Cite

Epidermal growth factor receptor (EGFR) inhibitors are a new biologically targeted therapy, which may offer new hope in the treatment of patients with advanced or recurrent ovarian cancers. In this review, we summarize and discuss the results of research to date on EGFR inhibitors with particular emphasis on ovarian cancer. We reviewed data identified by searches of MEDLINE, PubMed, and abstracts from the proceedings of the American Society of Clinical Oncology meetings from 1998 to 2006, with the search terms "Ovarian Cancer,""EGFR,""gefitinib, ZD1839, Iressa,""erlotinib, OSI-774, Tarceva,""CI-1033,"" GW 572016, lapatinib,""PKI-166,""EKB 569,""anti-EGFR antibodies,""trastuzumab, Herceptin,""cetuximab, Erbitux, IMC-C225,""matuzumab, EMD 72000,""panitumamab, ABX-EGF,""pertuzumab," and "vandetanib, rINN, Zactima, ZD6474." Phase II trials of both small molecule inhibitors of EGFR- and antibody-based inhibitors are currently ongoing in ovarian cancer and emerging data suggest that their activity in unselected women with advanced or recurrent ovarian cancer is modest, when utilized as a single agent. It is possible that these agents will be highly effective in smaller subsets of patients whose tumors are dependent on EGFR signaling, perhaps through activating mutations in EGFR or its downstream pathway. Targeted therapy with EGFR inhibitors is an untapped potential resource in the treatment of advanced or recurrent ovarian cancer. Ongoing trials will elucidate the most effective strategies to use these agents individually or in combination with traditional chemotherapeutic agents.

show abstract

Section: Canertinib/ci-1033mentioning

confidence: 99%

The emerging role of epidermal growth factor receptor inhibitors in ovarian cancer

Palayekar

Herzog

2008

Int J Gynecol Cancer

View full text Add to dashboard Cite

show abstract

“…No objective tumor responses were demonstrated, although six patients had the stable disease for > 3 months. A minimal antitumor activity of carnetinib was observed in platinum-refractory ovarian cancer patients [57].…”

Section: Carnetinibmentioning

confidence: 99%

Epidermal growth factor receptor inhibitors in non-small-cell lung cancer

Cascone¹,

Martinelli²,

Morelli³

et al. 2007

Expert Opinion on Drug Discovery

View full text Add to dashboard Cite

The epidermal growth factor receptor (EGFR) is a cell membrane receptor that plays a key role in cancer development and in the progression of many human malignancies, including non-small-cell lung cancer (NSCLC). EGFR-dependent signaling is involved in cancer cell proliferation, apoptosis, angiogenesis, invasion and metastasis. Targeting the EGFR is a valuable molecular approach in cancer therapy. This receptor is overexpressed in up to 80% of NSCLC cases. Thus, several molecules inhibiting this critical biologic pathway have been synthesized and tested as a single agent or in combination with other anticancer modalities in a wide of clinical trials, including reversible and irreversible small tyrosine kinase inhibitors, such as gefitinib and erlotinib, dual vascular endothelial growth factor receptor EGFR tyrosine kinase inhibitors, such as vandetanib (ZD-6474), and monoclonal antibodies, such as cetuximab, which have shown promising activity in patients with NSCLC. This review focuses on the preclinical and clinical results available with EGFR inhibitors in the treatment of NSCLC patients.

show abstract

“…Phase I trials [36] of CI-1033 in patients with solid tumors defined the DLTs to be acneiform rash, emesis, and diarrhea. • This led the way for a randomized phase II, single-agent study [37] of CI-1033 in ovarian cancer patients with tumors that were refractory to platinum therapy. Campos et al [37] presented preliminary findings at ASCO 2004.…”

Section: Ci-1033mentioning

confidence: 99%

“…• This led the way for a randomized phase II, single-agent study [37] of CI-1033 in ovarian cancer patients with tumors that were refractory to platinum therapy. Campos et al [37] presented preliminary findings at ASCO 2004. Patients were randomized to either a 50 mg or 200 mg dosage of CI-1033 taken orally for 21 days of a 28-day-cycle.…”

Section: Ci-1033mentioning

confidence: 99%

Rationale and clinical experience with epidermal growth factor receptor inhibitors in gynecologic malignancies

Vaidya¹,

Parnes²,

Seiden

2005

Curr. Treat. Options in Oncol.

View full text Add to dashboard Cite

The family of epidermal growth factor receptors (EGFRs) is overexpressed in many gynecologic malignancies. Extensive preclinical studies of these receptors demonstrate that they play an important role in supporting the growth of a wide variety of malignancies and that interruption of receptor function or signaling from these receptors leads to inhibition of tumor growth or in certain cases tumor regression. Recently, many therapeutic agents targeting this receptor have entered the clinic and phase II clinical studies have demonstrated activity in lung cancer, colon cancer, and head and neck malignancies. Phase II trials of both small molecule inhibitors of EGFR and antibody-based inhibitors are underway in both cervical and ovarian cancer and emerging data suggests that their activity in unselected women with advanced gynecologic malignancies is very modest. Recently, molecular analysis of lung cancers has identified that the response to small molecule inhibitors of EGFR is highly correlated with activating mutations within the EGFR. It is possible that these agents will be highly effective in a small subset of patients with gynecologic malignancies whose tumors are dependent on EGFR signaling, perhaps through an activating mutation in EGFR or its downstream pathway. Until additional research can identify the subset of patients most likely to benefit from this targeted therapy, treatment for women with gynecologic malignancies with EGFR inhibitors should be limited to investigational trials. It is critical that these trials have access to tissue of responding and nonresponding patients so to determine the rational use of these agents in the treatment of gynecologic malignancies.

show abstract

A phase 2, single agent study of CI-1033 administered at two doses in ovarian cancer patients who failed platinum therapy

Cited by 13 publications

References 0 publications

The emerging role of epidermal growth factor receptor inhibitors in ovarian cancer

The emerging role of epidermal growth factor receptor inhibitors in ovarian cancer

Epidermal growth factor receptor inhibitors in non-small-cell lung cancer

Rationale and clinical experience with epidermal growth factor receptor inhibitors in gynecologic malignancies

Contact Info

Product

Resources

About